Lupin launches Fluoxetine Tablets

Pharma major Lupin announced the launch of Fluoxetine Tablets USP, 60mg, having received approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Fluoxetine Tablets USP, 60mg, is the generic version of Alvogen Group Holdings 3 LLC’s Fluoxetine Tablets, 60mg. It is indicated in the treatment of Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Bulimia Nervosa, Panic disorder with or without agoraphobia.

Fluoxetine Tablets, 60mg had annual sales of approximately US$ 41 million in the US (IQVIA MAT February 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a global leadership position in the Anti-TB segment.

On Wednesday, the shares of Lupin opened at Rs. 807 against Tuesday’s close of Rs. 809. The shares at the end of the day closed at Rs 803.95, down by 0.65 per cent on the BSE. It reached an intraday high of Rs. 817.25 and an intraday low of Rs 799.40 per share on the BSE. The 52-week high stood at Rs. 986 and the 52-week low was at Rs. 720.40 per share on the BSE.